Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Miconazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 12/20 | 0.89 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.89 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.89 |
| ▸ | LMNA | P02545 | 4/20 | 0.89 |
| ▸ | NR1I2 | O75469 | 4/20 | 0.89 |
| ▸ | PGR | P06401 | 4/20 | 0.89 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.89 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.89 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.89 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.89 |
| ▸ | DRD3 | P35462 | 4/20 | 0.89 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.89 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.89 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.89 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.89 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.89 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.89 |
| ▸ | CNR1 | P21554 | 3/20 | 0.89 |
| ▸ | MC3R | P41968 | 3/20 | 0.89 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Econazole SCHEMBL34498 | 0.94 | IDO1 (1.00) | IDO1CYP2C9CYP3A4LMNANR1I2 | |
| Econazole SCHEMBL7602993 | 0.94 | IDO1 (1.00) | IDO1CYP2C9CYP3A4LMNANR1I2 | |
| Econazole SCHEMBL7602990 | 0.94 | IDO1 (1.00) | IDO1CYP2C9CYP3A4LMNANR1I2 | |
| Econazole SCHEMBL34499 | 0.94 | IDO1 (1.00) | IDO1CYP2C9CYP3A4LMNANR1I2 | |
| Econazole SCHEMBL20482166 | 0.94 | IDO1 (1.00) | IDO1CYP2C9CYP3A4LMNANR1I2 | |
| Econazole SCHEMBL29440264 | 0.94 | IDO1 (1.00) | IDO1CYP2C9CYP3A4LMNANR1I2 | |
| Miconazole SCHEMBL9662051 | 0.94 | IDO1 (1.00) | IDO1CYP2C9CYP3A4LMNANR1I2 | |
| (R)-Miconazole SCHEMBL30594078 | 0.94 | IDO1 (1.00) | IDO1CYP2C9CYP3A4LMNANR1I2 | |
| Miconazole SCHEMBL2866 | 0.94 | IDO1 (1.00) | IDO1CYP2C9CYP3A4LMNANR1I2 | |
| Miconazole SCHEMBL7647866 | 0.94 | IDO1 (1.00) | IDO1CYP2C9CYP3A4LMNANR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005053613-A2 | COMBINATIONS FOR THE TREATMENT OF FUNGAL INFECTIONS | COMBINATORX, INC. (US) | 2005-06-16 | — | — | WO | claimed |
| US-4484925-A | USING BIOCIDAL AGENTS ON METAL COMPLEXES | ROUX JOEL (FR) | 1984-11-27 | — | — | US | claimed |
| WO-2019046303-A1 | A METHOD FOR PREDICTING A SUBJECT'S RESPONSE TO SLC MODULATOR THERAPY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2019-03-07 | — | — | WO | disclosed |
| US-9254330-B2 | Biotherapeutics for the treatment of infectious diseases | BIOLOGICAL RESPONSIBILITY, LLC (US) | 2016-02-09 | — | — | US | disclosed |
| US-20140350063-A1 | BIOTHERAPEUTICS FOR THE TREATMENT OF INFECTIOUS DISEASES | BIOLOGICAL RESPONSIBILITY, LLC (US) | 2014-11-27 | — | — | US | disclosed |
| US-8846740-B2 | Biotherapeutics for the treatment of infectious diseases | BIOLOGICAL RESPONSIBILITY, LLC (US) | 2014-09-30 | — | — | US | disclosed |
| US-20120172342-A1 | Biotherapeutics For the Treatment of Infectious Diseases | BIOLOGICAL RESPONSIBILITY, LLC | 2012-07-05 | — | — | US | disclosed |
| WO-2010029313-A1 | ANTIINFECTIVE COMPOUNDS | SUMMIT CORPORATION PLC. (GB) | 2010-03-18 | — | — | WO | disclosed |
| US-20070299043-A1 | Anti-scarring drug combinations and use thereof | HUNTER WILLIAM L | 2007-12-27 | — | — | US | disclosed |
| US-20070208134-A1 | Anti-scarring drug combinations and use thereof | HUNTER WILLIAM L | 2007-09-06 | — | — | US | disclosed |
| US-20070197957-A1 | Implantable sensors, implantable pumps and anti-scarring drug combinations | HUNTER WILLIAM L | 2007-08-23 | — | — | US | disclosed |
| WO-2007041463-A2 | ELECTRICAL DEVICES AND ANTI-SCARRING DRUG COMBINATIONS | COMBINATORX, INCORPORATED (US) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007041593-A2 | ANTI-SCARRING DRUG COMBINATIONS AND USE THEREOF | COMBINATORX, INCORPORATED (US) | 2007-04-12 | — | — | WO | disclosed |
| WO-2005082054-A2 | COMBINATIONS FOR THE TREATMENT OF FUNGAL INFECTIONS | SOSEI CO., LTD. (JP) | 2005-09-09 | — | — | WO | disclosed |
| WO-2005060951-A2 | ANTI-NEOPLASTIC AGENTS, COMBINATION THERAPIES AND RELATED METHODS | BIONAUT PHARMACEUTICALS, INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005053613-A2 | COMBINATIONS FOR THE TREATMENT OF FUNGAL INFECTIONS | COMBINATORX, INC. (US) | 2005-06-16 | — | — | WO | disclosed |
| WO-2002005850-A2 | ENHANCEMENT OF THE ACTION OF ANTI-INFECTIVE AGENTS | PITMY INTERNATIONAL N.V. (AN) | 2002-01-24 | — | — | WO | disclosed |
| US-5683713-A | TRANSDERMAL PENETRATION FOR ANTIOXIDANTS OF MERCAPTOACIDS, MERCAPTOESTERS AND AMIDES | BLANK IZHAK (IL) | 1997-11-04 | — | — | US | disclosed |
| EP-0712633-A1 | Pharmaceutical compositions for topical application | Blank, Izhak (IL) | 1996-05-22 | — | — | EP | disclosed |
| WO-1995016465-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING ALKYL POLYOXYALKYLENE CARBOXYLATES | SANDOZ LTD. (CH) | 1995-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208134-A1 | Anti-scarring drug combinations and use thereof | MMP1, COL2A1, COL1A1 | IDO1 317/4885CYP2C9 2640/4885CYP3A4 3448/4885 |
| US-20070299043-A1 | Anti-scarring drug combinations and use thereof | MMP1, COL2A1, COL1A1 | IDO1 317/4885CYP2C9 2640/4885CYP3A4 3448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.